Sanofi pays up to USD 1bn for new multiple myeloma therapy

Following a licensing agreement with Eureka Therapeutics, Sanofi has acquired another drug candidate for multiple myeloma to join its portfolio alongside Sarclisa.

Photo: CHARLES PLATIAU/Reuters / X00217

Sanofi is paying an undisclosed amount to forge a new license agreement with Eureka Therapeutics. However, the value of the deal might reach USD 1bn in subsequent milestone payments, according to a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs